Introduction: BRAF mutations in advanced stage colorectal cancers are observed in 8-12% of patients and BRAF V600E is the most frequent alteration. This mutation confers poor prognosis and treatment outcomes with routine systemic chemotherapy
Search Results
Mackenzie Taychert, Ankita Aggarwal, David Tabagari, Urja Nagadia, Sai Gajagowni, Venkata Vosuri, and Kushal Naha
Andrew J. Portuguese, Scott S. Tykodi, Christopher D. Blosser, Ted A. Gooley, John A. Thompson, and Evan T. Hall
are now eligible for treatment with ICIs. 8 Due to the need for chronic immunosuppressive therapy, SOTRs with cancer have been consistently excluded from clinical trials with ICIs. 9 – 16 Thus, clinical outcomes for cancers arising in SOTRs treated
Puneeth Iyengar and Robert D. Timmerman
To understand why radiation oncologists moved toward the use of SABR in treating primary NSCLCs and metastatic disease to the lungs, the poor outcomes in controlling these disease states with fractionated radiation therapy (eg, 25–37 daily treatments
Cary P. Gross, Craig S. Meyer, Sarika Ogale, Matthew Kent, and William B. Wong
in survival over the past decade. 2 Advances in personalized therapies for advanced NSCLC (aNSCLC), which allow treatment based on the genetic makeup of a tumor, have significantly contributed to the improved outcomes of patients. 2 Despite the
Kristen Kelley, Audrey York, Benjamin Haaland, Xuechen Wang, Shiven Patel, Adriana Coletta, and Christos Vaklavas
chemotherapy may be superior. The objective of this study is to assess the relationship between dose timing and outcomes in breast cancer patients. Methods : 153 patients who had neoadjuvant chemotherapy in 2014-2020 were included. Chemotherapy administration
Eric Chen, Todd Aquino-Michaels, Sadhvi Batra, Riley Lochner, Anthony Rizzo, Ravi Kyasaram, Eleanor Harris, Tiffany Hodges, Lindsay Ferguson, and Serah Choi
Background : Even among patients with stage IV gynecologic cancers, metastases to the brain are rare and prognosis remains poor. Given the paucity of data, this study aimed to describe the outcomes of this patient population who underwent
Krista Michelle Wong, Seshma Ramsawak, and Hasan Abuamsha
racial disparity in appendiceal cancer-specific survival exists among appendiceal cancer SEER patients. Further research is needed to address the underlying cause of these disparities in order to improve outcomes. Table: Bivariable and multivariable
Alejandro Garcia-Horton and Jeffrey H. Lipton
possible without widespread treatment and availability of TKIs, resulting in disease control and molecular response. Treatment-free remission (TFR) has emerged as a new goal for many patients with CML as a distinct outcome other than overall survival (OS
Kuan-Ling Kuo, David Stenehjem, Frederick Albright, Saurabh Ray, and Diana Brixner
, 31% (n=68) of patients received no treatment ( Table 3 ). From 1995 to 1998, most patients did not receive any treatment. Liver-directed therapy became more prevalent from 2007 to 2010 ( Figure 2 ). Survival Outcomes No statistically
Angela K. Green, Deborah Korenstein, Carol Aghajanian, Brooke Barrow, Michael Curry, and Roisin E. O’Cearbhaill
supporting evidence that it improves outcomes. 1 , 2 Yet imaging, either in response to patient symptoms or for surveillance, is common in the management of patients with ovarian cancer in first remission among providers at academic medical centers. 3 In a